Department of Breast and Sarcoma Surgery, National Institute of Oncology, Budapest, Hungary.
Department of Pathology, Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary; Department of Pathology, University of Szeged, Szeged, Hungary.
Eur J Surg Oncol. 2019 Oct;45(10):1835-1838. doi: 10.1016/j.ejso.2019.05.016. Epub 2019 May 16.
Ipsilateral breast recurrence or second primary breast cancer can develop in patients who have undergone breast conserving surgery (BCS) and axillary surgery. The purpose of this study was to examine the feasibility of a reoperative sentinel lymph node biopsy (SLNB) as a repeated axillary staging procedure.
From August 2014 through January 2017 patients with locally recurrent breast cancer or with BRCA mutation requiring risk reduction mastectomy as a second surgical procedure, underwent repeat SLNB in three Hungarian Breast Units with a radiocolloid (and blue dye) technique.
Hundred and sixty repeat SLNBs were analysed, 80 after previous SLNB and 80 after previous total or partial axillary lymph node dissection (ALND). SLN identification was successful in 106 patients (66%); 77/80 (77.5%) and 44/80 (55%) in the SLNB and ALND groups, respectively. (p < 0.003). Extra-axillary lymph drainage was more frequent in the ALND group (19/44, 43,2% versus 7/62, 11,3%; p < 0.001). Lymphatic drainage to the contralateral axilla was observed in 14 patients (11 in the ALND group, p = 0.025), isolated parasternal drainage was detected in 4 patients (p = 0.31). Only 9/106 patients with successful repeat SLNB (8,8%, all with 1 SLN removed) had SLN metastases CONCLUSIONS: Repeat SLNB is feasible in patients with ipsilateral breast tumor recurrence or new ipsilateral primary tumor after previous BCS and axillary staging. Repeat SLNB should replace routine ALND as the standard axillary restaging procedure in recurrent disease with a clinically negative axilla. Preoperative lymphoscintigraphy is important to explore extra-axillary lymphatic drainage in this restaging setting.
接受保乳手术(BCS)和腋窝手术的患者可能会发生同侧乳房复发或第二原发性乳腺癌。本研究的目的是研究再次进行前哨淋巴结活检(SLNB)作为重复腋窝分期程序的可行性。
从 2014 年 8 月到 2017 年 1 月,3 家匈牙利乳房单位的局部复发性乳腺癌或需要降低风险的乳腺癌 BRCA 突变患者接受了放射性胶体(和蓝色染料)技术的重复 SLNB。
分析了 160 次重复 SLNB,80 次在前哨淋巴结活检后,80 次在前哨淋巴结清扫术(ALND)后。106 例患者(66%)成功识别 SLN,80/80(77.5%)和 44/80(55%)分别在 SLNB 和 ALND 组中。(p <0.003)。ALND 组中出现额外腋窝淋巴引流的情况更为常见(19/44,43.2%比 7/62,11.3%;p <0.001)。14 例患者(ALND 组中有 11 例)观察到对侧腋窝的淋巴引流,4 例患者(p = 0.31)检测到孤立性胸骨旁引流。只有 106 例成功重复 SLNB 的患者中有 9 例(9/106,8.8%,均为 1 个 SLN 切除)有 SLN 转移。
在先前 BCS 和腋窝分期后同侧乳房肿瘤复发或同侧新原发性肿瘤的患者中,重复 SLNB 是可行的。在临床阴性腋窝的复发性疾病中,重复 SLNB 应替代常规 ALND 作为标准的腋窝再分期程序。在这种再分期环境中,术前淋巴闪烁显像对于探索额外腋窝淋巴引流很重要。